Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 31, 2019 18:00 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 31, 2019,...
Sarepta Therapeutics Enters into Long-term Strategic Relationship with Aldevron for GMP-grade Plasmid in Support of Gene Therapy Development and Commercial Manufacturing Strategy
January 02, 2019 08:30 ET
|
Sarepta Therapeutics, Inc.
-- Agreement provides Sarepta with committed capacity and dedicated manufacturing slots for GMP-grade plasmid production for its micro-dystrophin Duchenne muscular dystrophy (DMD) gene therapy...
Sarepta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 02, 2019 08:00 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, today announced that management will present...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 31, 2018 18:00 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 31, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2018,...
Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
December 20, 2018 08:30 ET
|
Sarepta Therapeutics, Inc.
-- Golodirsen has been studied for the treatment of exon 53 amenable patients, approximately eight percent of patients with Duchenne ---- Submission represents ongoing advancement of the company’s...
Sarepta Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors
December 11, 2018 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it appointed Mary Ann...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 30, 2018 18:00 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 30, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, granted equity awards on November 30, 2018,...
Sarepta Therapeutics Announces Pricing of $500,000,000 Public Offering of Common Stock
November 08, 2018 19:13 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, today announced that it has priced an...
Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock
November 07, 2018 16:21 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, today announced that it is offering to sell,...
Sarepta Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference
November 02, 2018 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, today announced that management will present...